Recently Expired Drugs
1. Admelog Solostar patent expiration
ADMELOG SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI-AVENTIS US | Pen-type injector |
Apr, 2025
(9 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 11, 2020 |
Drugs and Companies using INSULIN LISPRO ingredient
Market Authorisation Date: 11 December, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ADMELOG SOLOSTAR family patents
2. Ampyra patent expiration
AMPYRA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8440703 | MERZ | Methods of using sustained release aminopyridine compositions |
Apr, 2025
(13 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2015 |
| Orphan Drug Exclusivity(ODE) | Jan 22, 2017 |
Drugs and Companies using DALFAMPRIDINE ingredient
NCE-1 date: 22 January, 2014
Market Authorisation Date: 22 January, 2010
Treatment: Improvement of walking in patients with multiple sclerosis (ms)
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AMPYRA before it's drug patent expiration?
More Information on Dosage
AMPYRA family patents
3. Apidra Solostar patent
expiration
APIDRA SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI AVENTIS US | Pen-type injector |
Apr, 2025
(9 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 24, 2011 |
Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient
Market Authorisation Date: 16 April, 2004
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
APIDRA SOLOSTAR family patents
4. Bydureon patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(8 days ago) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(8 days ago) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(8 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2015 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adju...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON family patents
5. Bydureon Bcise patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(8 days ago) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(8 days ago) | |
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(8 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 20, 2020 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; Improving glycemic control in patients 10 years ...
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON BCISE family patents
6. Bydureon Pen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(8 days ago) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(8 days ago) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(8 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet ...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON PEN family patents
7. Cabenuva Kit patent expiration
CABENUVA KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(18 hours ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-184) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
CABENUVA KIT family patents
8. Complera patent expiration
COMPLERA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(18 hours ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
| New Patient Population(NPP) | Dec 13, 2016 |
NCE-1 date: 21 May, 2015
Market Authorisation Date: 10 August, 2011
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of COMPLERA before it's drug patent expiration?
More Information on Dosage
COMPLERA family patents
9. Contrave patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7375111 | NALPROPION | Compositions for affecting weight loss |
Mar, 2025
(26 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 10, 2017 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage
CONTRAVE family patents
10. Edurant patent expiration
EDURANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(18 hours ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
| New Patient Population(NPP) | Aug 26, 2018 |
| M(M-223) | Feb 01, 2021 |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 21 May, 2015
Market Authorisation Date: 20 May, 2011
Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive adult patients with hiv-1 rna less than or equal to 100,000 at the start of therapy
Dosage: TABLET
More Information on Dosage
EDURANT family patents
11. Edurant Ped patent expiration
EDURANT PED's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(18 hours ago) | |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 March, 2024
Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in antiretroviral treatment-naive patients 2 years of age and older, weighing at least 14kg, with hiv-1 rna less th...
Dosage: TABLET, FOR SUSPENSION
More Information on Dosage
EDURANT PED family patents
12. Farxiga patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(8 days ago) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(8 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-157) | Mar 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-212) | Oct 20, 2020 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Indication(I-834) | May 05, 2023 |
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide
Dosage: TABLET
How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage
FARXIGA family patents
13. Forteo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7517334 | LILLY | Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose |
Mar, 2025
(27 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-602) | Jul 22, 2012 |
| M(M-302) | Nov 16, 2023 |
Drugs and Companies using TERIPARATIDE ingredient
Market Authorisation Date: 25 June, 2008
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of FORTEO before it's drug patent expiration?
More Information on Dosage
FORTEO family patents
14. Glumetza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7780987 | SANTARUS INC | Controlled release dosage forms |
Mar, 2025
(29 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8323692 | SANTARUS INC | Controlled release dosage forms |
Mar, 2025
(29 days ago) | |
Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 03 June, 2005
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of GLUMETZA before it's drug patent expiration?
More Information on Dosage
GLUMETZA family patents
15. Horizant patent expiration
HORIZANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6818787 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Apr, 2025
(15 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-652) | Jun 06, 2015 |
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Jun 06, 2019 |
| Orphan Drug Exclusivity(ODE-25) | Jun 06, 2019 |
Drugs and Companies using GABAPENTIN ENACARBIL ingredient
NCE-1 date: 07 April, 2015
Market Authorisation Date: 13 December, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of HORIZANT before it's drug patent expiration?
More Information on Dosage
HORIZANT family patents
16. Invokamet patent expiration
INVOKAMET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(10 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Patient Population(NPP) | Dec 18, 2027 |
| Pediatric Exclusivity(PED) | Jun 18, 2028 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 19 June, 2027
Market Authorisation Date: 08 August, 2014
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET
How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage
INVOKAMET family patents
17. Invokamet Xr patent expiration
INVOKAMET XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(10 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| New Indication(I-788) | Oct 29, 2021 |
| New Patient Population(NPP) | Dec 18, 2027 |
| Pediatric Exclusivity(PED) | Jun 18, 2028 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 19 June, 2027
Market Authorisation Date: 20 September, 2016
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage
INVOKAMET XR family patents
18. Invokana patent expiration
INVOKANA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(10 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-733) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Indication(I-809) | Sep 27, 2022 |
| New Patient Population(NPP) | Dec 18, 2027 |
| Pediatric Exclusivity(PED) | Jun 18, 2028 |
Drugs and Companies using CANAGLIFLOZIN ingredient
NCE-1 date: 19 June, 2027
Market Authorisation Date: 29 March, 2013
Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET
How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage
INVOKANA family patents
19. Juluca patent expiration
JULUCA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(18 hours ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Combination(NC) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 21 November, 2017
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of JULUCA before it's drug patent expiration?
More Information on Dosage
JULUCA family patents
20. Kyprolis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8207125 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(7 days ago) | |
| US7232818 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(7 days ago) | |
| US8207297 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(7 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8207127 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(7 days ago) | |
| US8129346 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(7 days ago) | |
| US7491704 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(7 days ago) | |
| US8207126 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(7 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2017 |
| New Indication(I-712) | Jul 24, 2018 |
| New Indication(I-722) | Jan 21, 2019 |
| New Indication(I-723) | Jan 21, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 20, 2019 |
| Orphan Drug Exclusivity(ODE-27) | Jul 20, 2019 |
| New Dosing Schedule(D-172) | Sep 28, 2021 |
| New Indication(I-842) | Aug 20, 2023 |
Drugs and Companies using CARFILZOMIB ingredient
NCE-1 date: 20 July, 2016
Market Authorisation Date: 07 June, 2018
Treatment: Kyprolis is indicated in combination with daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; Kyp...
Dosage: POWDER
How can I launch a generic of KYPROLIS before it's drug patent expiration?
More Information on Dosage
KYPROLIS family patents
21. Lantus Solostar patent expiration
LANTUS SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI AVENTIS US | Pen-type injector |
Apr, 2025
(9 days ago) | |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
LANTUS SOLOSTAR family patents
22. Odefsey patent expiration
ODEFSEY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125879 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(18 hours ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-206) | Aug 21, 2020 |
| M(M-207) | Aug 21, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 01 March, 2016
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of ODEFSEY before it's drug patent expiration?
More Information on Dosage
ODEFSEY family patents
23. Oraverse patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7575757 | SEPTODONT HOLDING | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Apr, 2025
(18 hours ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 18, 2019 |
Drugs and Companies using PHENTOLAMINE MESYLATE ingredient
Market Authorisation Date: 09 May, 2008
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
ORAVERSE family patents
24. Oxycontin patent expiration
OXYCONTIN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(22 days ago) | |
| US10407434 | PURDUE PHARMA LP | Process for preparing oxycodone compositions |
Mar, 2025
(22 days ago) | |
| US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(22 days ago) | |
| US10696684 | PURDUE PHARMA LP | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(22 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7683072 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(22 days ago) | |
| US7674799 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(22 days ago) | |
| US7674800 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(22 days ago) | |
| US12060361 | PURDUE PHARMA LP | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(22 days ago) | |
| US7776314 | PURDUE PHARMA LP | Abuse-proofed dosage system |
Apr, 2025
(2 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-153) | Apr 16, 2016 |
| New Patient Population(NPP) | Aug 13, 2018 |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 12 December, 1995
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OXYCONTIN family patents
25. Protonix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7550153 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(22 days ago) | |
|
US7553498 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(22 days ago) | |
|
US7838027 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(22 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-614) | Nov 12, 2012 |
| M(M-54) | Nov 12, 2012 |
| Pediatric Exclusivity(PED) | May 12, 2013 |
Drugs and Companies using PANTOPRAZOLE SODIUM ingredient
Market Authorisation Date: 14 November, 2007
Treatment: NA
Dosage: FOR SUSPENSION, DELAYED RELEASE
How can I launch a generic of PROTONIX before it's drug patent expiration?
More Information on Dosage
PROTONIX family patents
26. Soliqua 100/33 patent expiration
SOLIQUA 100/33 IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI-AVENTIS US | Pen-type injector |
Apr, 2025
(9 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
SOLIQUA 100/33 family patents
27. Symtuza patent expiration
SYMTUZA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7390791 | JANSSEN PRODS | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(4 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Combination(NC) | Jul 17, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 17 July, 2018
Treatment: NA
Dosage: TABLET
How can I launch a generic of SYMTUZA before it's drug patent expiration?
More Information on Dosage
SYMTUZA family patents
28. Targiniq patent expiration
TARGINIQ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7683072 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(22 days ago) | |
| US7674800 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(22 days ago) | |
| US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(22 days ago) | |
| US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(22 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7674799 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(22 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 23, 2017 |
Drugs and Companies using NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 July, 2014
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
TARGINIQ family patents
29. Tegsedi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8101743 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2025
(20 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2023 |
| Orphan Drug Exclusivity(ODE-212) | Oct 05, 2025 |
Drugs and Companies using INOTERSEN SODIUM ingredient
NCE-1 date: 05 October, 2022
Market Authorisation Date: 05 October, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TEGSEDI family patents
30. Toujeo Max Solostar patent expiration
TOUJEO MAX SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI US SERVICES | Pen-type injector |
Apr, 2025
(9 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TOUJEO MAX SOLOSTAR family patents
31. Toujeo Solostar patent expiration
TOUJEO SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679069 | SANOFI US SERVICES | Pen-type injector |
Apr, 2025
(9 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2018 |
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TOUJEO SOLOSTAR family patents
32. Wainua (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8101743 | ASTRAZENECA AB | Modulation of transthyretin expression |
Apr, 2025
(20 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2028 |
| Orphan Drug Exclusivity(ODE-461) | Dec 21, 2030 |
Drugs and Companies using EPLONTERSEN SODIUM ingredient
NCE-1 date: 22 December, 2027
Market Authorisation Date: 21 December, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
WAINUA (AUTOINJECTOR) family patents
33. Xtampza Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7771707 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Mar, 2025
(28 days ago) | |
| US8449909 | COLLEGIUM PHARM INC | Abuse-deterrent drug formulations |
Mar, 2025
(28 days ago) | |
| US7399488 | COLLEGIUM PHARM INC | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
Mar, 2025
(28 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 26, 2019 |
Drugs and Companies using OXYCODONE ingredient
Market Authorisation Date: 26 April, 2016
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of XTAMPZA ER before it's drug patent expiration?
More Information on Dosage
XTAMPZA ER family patents